Corcept Therapeutics Inc. Stock
The price for the Corcept Therapeutics Inc. stock decreased slightly today. Compared to yesterday there is a change of -€0.320 (-0.440%).
With 11 Buy predictions and not the single Sell prediction the community is currently very high on Corcept Therapeutics Inc..
With a target price of 124 € there is a hugely positive potential of 71.18% for Corcept Therapeutics Inc. compared to the current price of 72.44 €.
Our community identified positive and negative aspects for Corcept Therapeutics Inc. stock for the coming years. 0 users see the criterium "Worthwhile Investment for the next years" as a plus for the Corcept Therapeutics Inc. stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
Pros and Cons of Corcept Therapeutics Inc. in the next few years
Pros
?
M***** P*******
?
C******** o* t** e**********
?
G***** c******* t* c**********
Cons
?
B****
?
S********** s********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Corcept Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Corcept Therapeutics Inc. | -0.440% | 5.756% | 17.582% | 25.708% | 46.075% | 207.134% | 273.128% |
| Pacira Pharmaceuticals | 0.000% | 1.000% | 4.663% | 30.323% | 9.189% | -54.091% | -59.274% |
| Rockwell Medical Inc. | 2.130% | 3.742% | -3.427% | -60.305% | -58.061% | -21.713% | -91.735% |
| Twist Bioscience Corp | -0.750% | 3.414% | 7.601% | -43.513% | -38.399% | 4.083% | -73.425% |
Comments
Corcept Therapeutics (NASDAQ:CORT) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $145.00 price target on the stock.
Show more
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics (NASDAQ:CORT) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $145.00 price target on the stock.
Show more
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics (NASDAQ:CORT) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $145.00 price target on the stock.
Show more
Ratings data for CORT provided by MarketBeat